WO2006007671A3 - Combinaisons therapeutiques - Google Patents

Combinaisons therapeutiques Download PDF

Info

Publication number
WO2006007671A3
WO2006007671A3 PCT/BE2005/000112 BE2005000112W WO2006007671A3 WO 2006007671 A3 WO2006007671 A3 WO 2006007671A3 BE 2005000112 W BE2005000112 W BE 2005000112W WO 2006007671 A3 WO2006007671 A3 WO 2006007671A3
Authority
WO
WIPO (PCT)
Prior art keywords
therapeutically
combinations
administration
betaine
cholesterol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/BE2005/000112
Other languages
English (en)
Other versions
WO2006007671A2 (fr
Inventor
Jallal Messadek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to PL05763958T priority Critical patent/PL1773450T3/pl
Priority to AT05763958T priority patent/ATE498427T1/de
Priority to DK05763958.5T priority patent/DK1773450T3/da
Priority to DE602005026394T priority patent/DE602005026394D1/de
Priority to EP05763958A priority patent/EP1773450B1/fr
Publication of WO2006007671A2 publication Critical patent/WO2006007671A2/fr
Publication of WO2006007671A3 publication Critical patent/WO2006007671A3/fr
Priority to US11/625,448 priority patent/US20070134324A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Le but de la présente invention est une composition pharmaceutique comprenant une betaine et un agent anti-cholesterol. L'association et la co-administration d'au moins une bétaine permettant de réduire les effets secondaires liés à l'administration des agents anti-cholesterol, notamment leurs effets délérères sur le foie, le pancréas et les reins.
PCT/BE2005/000112 2004-07-22 2005-07-13 Combinaisons therapeutiques Ceased WO2006007671A2 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
PL05763958T PL1773450T3 (pl) 2004-07-22 2005-07-13 Kompozycja farmaceutyczna
AT05763958T ATE498427T1 (de) 2004-07-22 2005-07-13 Therapeutische kombinationen
DK05763958.5T DK1773450T3 (da) 2004-07-22 2005-07-13 Terapeutiske kombinationer
DE602005026394T DE602005026394D1 (de) 2004-07-22 2005-07-13 Therapeutische kombinationen
EP05763958A EP1773450B1 (fr) 2004-07-22 2005-07-13 Combinaisons therapeutiques
US11/625,448 US20070134324A1 (en) 2004-07-22 2007-01-22 Therapeutic combinations

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
BEBE2004/0364 2004-07-22
BE2004/0364A BE1016128A6 (fr) 2004-07-22 2004-07-22 Combinaisons therapeutiques

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/625,448 Continuation-In-Part US20070134324A1 (en) 2004-07-22 2007-01-22 Therapeutic combinations

Publications (2)

Publication Number Publication Date
WO2006007671A2 WO2006007671A2 (fr) 2006-01-26
WO2006007671A3 true WO2006007671A3 (fr) 2006-02-23

Family

ID=35462104

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/BE2005/000112 Ceased WO2006007671A2 (fr) 2004-07-22 2005-07-13 Combinaisons therapeutiques

Country Status (10)

Country Link
US (1) US20070134324A1 (fr)
EP (1) EP1773450B1 (fr)
AT (1) ATE498427T1 (fr)
BE (1) BE1016128A6 (fr)
DE (1) DE602005026394D1 (fr)
DK (1) DK1773450T3 (fr)
ES (1) ES2361284T3 (fr)
PL (1) PL1773450T3 (fr)
PT (1) PT1773450E (fr)
WO (1) WO2006007671A2 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE1015608A6 (fr) 2003-07-15 2005-06-07 Messadek Jallal Traitement des arterites.
ES2278314T3 (es) * 2003-04-17 2007-08-01 Jallal Messadek Formulaciones orales para la liberacion controlada de la betaina.
US7785740B2 (en) * 2004-04-09 2010-08-31 Air Products And Chemicals, Inc. Overcharge protection for electrochemical cells
WO2006050581A2 (fr) 2004-11-10 2006-05-18 Jallal Messadek Betaine en tant qu'agent de lutte contre des maladies transmises par des arthropodes ou des moustiques
WO2006086856A1 (fr) 2005-02-15 2006-08-24 Messadek, Jallal Compositions therapeutiques combinees et leurs procedes d’utilisation
ATE540690T1 (de) 2005-04-27 2012-01-15 Jallal Messadek Insulinkombinationen
KR20100015343A (ko) * 2007-03-01 2010-02-12 컨커스 헬스 사이언스 엘엘씨 이노시톨 니아시네이트의 이성질체 및 그 용도
WO2009065193A1 (fr) * 2007-11-21 2009-05-28 Jallal Messadek Traitement de la résistance à l'aspirine par de la bétaïne et/ou de la mélasse enrichie en bétaïne
CN102421423B (zh) 2009-05-12 2014-11-05 Bpsi控股有限责任公司 增强型防潮即释薄膜包衣系统和覆有该包衣的基体
AU2010248061A1 (en) * 2009-05-12 2011-10-27 Bpsi Holdings, Llc. Film coatings containing fine particle size detackifiers and substrates coated therewith
KR101296328B1 (ko) * 2009-09-21 2013-08-14 주식회사 삼양바이오팜 피브레이트계 약물을 포함하는 고체분산체 및 이의 제조방법
WO2025144770A1 (fr) * 2023-12-29 2025-07-03 Complete Solution For Poultry (Csp), Inc. Produits de bétaïne de haute pureté, produits de polyphénol et leurs procédés de fabrication

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19910682A1 (de) * 1999-03-10 2000-09-21 Jutta Dierkes Kombination von Fibraten mit einem oder mehreren Wirkstoffen, die den Homocysteinspiegel zu senken vermögen
US6235311B1 (en) * 1998-03-18 2001-05-22 Bristol-Myers Squibb Company Pharmaceutical composition containing a combination of a statin and aspirin and method
WO2002062322A2 (fr) * 2001-02-05 2002-08-15 Jallal Messadek Glycine-betaine et utilisation correspondante
WO2004049095A2 (fr) * 2002-11-25 2004-06-10 Jallal Messadek Compositions de betaine
WO2005011642A1 (fr) * 2003-08-05 2005-02-10 Galephar M/F Composition pharmaceutique a unite simple comprenant un melange de fibranne et un agent reducteur d'homocysteine

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US580098A (en) * 1897-04-06 Governor for water-motors
US3577534A (en) * 1968-06-20 1971-05-04 Canada Packers Ltd Stable orally active heparinoid complexes
GB1509979A (en) * 1975-11-28 1978-05-10 Fisons Ltd Pharmaceutical compositions containing aspirin or indomethacin
US4140755A (en) * 1976-02-13 1979-02-20 Hoffmann-La Roche Inc. Sustained release tablet formulations
US4605548A (en) * 1983-05-31 1986-08-12 Nitto Electric Industrial Co., Ltd. Drug administration material
GB8325627D0 (en) * 1983-09-24 1983-10-26 Scras Therapeutic compositions
DK162986A (da) * 1985-04-12 1986-10-13 Forest Laboratories Terapeutisk middel i enhedsdosisform
AU607172B2 (en) * 1986-12-22 1991-02-28 Cygnus, Inc. Diffusion matrix for transdermal drug administration
US4902718A (en) * 1988-04-08 1990-02-20 Bayless Robert K Calcium homeostasis compositions and methods for controlling calcium metabolism
US4968719A (en) * 1989-04-03 1990-11-06 Sigma Tau, Industrie Farmaceutiche Riunite Spa Method for treating vascular disease
EP0441119A3 (en) * 1990-01-09 1992-10-14 Richard D. Levere The use of l-arginine in the treatment of hypertension and other vascular disorders
US5405614A (en) * 1992-04-08 1995-04-11 International Medical Associates, Inc. Electronic transdermal drug delivery system
US5342621A (en) * 1992-09-15 1994-08-30 Advanced Cardiovascular Systems, Inc. Antithrombogenic surface
US5876780A (en) * 1993-04-29 1999-03-02 Cultor, Ltd. Compositions for treating coccidiosis
US5716941A (en) * 1993-07-07 1998-02-10 Biogenesys Use of methyl donor compounds to treat neurological dysfunction associated with immune defects
US5814599A (en) * 1995-08-04 1998-09-29 Massachusetts Insitiute Of Technology Transdermal delivery of encapsulated drugs
US6355166B1 (en) * 1994-08-25 2002-03-12 The University Of Iowa Research Foundation Magnetically enhanced composite materials and methods for making and using the same
US6056958A (en) * 1994-12-09 2000-05-02 Dupont Pharmaceuticals Method of treatment of arterial and venous thromboembolic disorders
US5961999A (en) * 1995-06-08 1999-10-05 Wella Aktiengesellschaft Method of skin care using a skin care preparation containing a betaine ester and an α-hydroxy acid
US6162926A (en) * 1995-07-31 2000-12-19 Sphere Biosystems, Inc. Multi-substituted fullerenes and methods for their preparation and characterization
US7045585B2 (en) * 1995-11-30 2006-05-16 Hamilton Civic Hospital Research Development Inc. Methods of coating a device using anti-thrombin heparin
WO1997027829A1 (fr) * 1996-01-31 1997-08-07 The Trustees Of The University Of Pennsylvania Dispositif d'administration de medicament commande a distance
US5688499A (en) * 1996-03-13 1997-11-18 Queen's University At Kingston Antagonism of endothelin actions
US5880098A (en) * 1996-04-12 1999-03-09 Pharmacia & Upjohn Aktiebolag Therapeutic treatment
IL119029A0 (en) * 1996-08-07 1996-11-14 Yeda Res & Dev Long-acting drugs and pharamaceutical compositions comprising them
US6008221A (en) * 1996-11-06 1999-12-28 Bristol-Myers Squibb Company Method for treating Alzheimer's disease with folic acid
US6495579B1 (en) * 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
US6287765B1 (en) * 1998-05-20 2001-09-11 Molecular Machines, Inc. Methods for detecting and identifying single molecules
US7608640B2 (en) * 1999-03-02 2009-10-27 Jallal Messadek Glycine betaine and its use
BE1012495A3 (fr) * 1999-03-02 2000-11-07 Messadek Jallal La glycine-betaine pour son usage antithrombotique.
EP1276465B1 (fr) * 2000-04-20 2014-03-12 Jagotec AG Procede ameliore destine aux particules de medicament insolubles dans l'eau
US6476006B2 (en) * 2000-06-23 2002-11-05 Teva Pharmaceutical Industries, Ltd. Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates
US6881420B2 (en) * 2000-06-23 2005-04-19 Teva Pharmaceutical Industries Ltd. Compositions and dosage forms for gastric delivery of irinotecan and methods of treatment that use it to inhibit cancer cell proliferation
FR2811227A1 (fr) * 2000-07-07 2002-01-11 Philippe Maincent Vecteurs particulaires destines a ameliorer l'absorption orale de principes actifs
MXPA03004458A (es) * 2000-11-20 2005-01-25 Pharmacia Corp Arilpiridinas y heteroarilpiridinas sustituidas utiles para inhibicion selectiva de la cascada de coagulacion.
FI114538B (fi) * 2001-01-12 2004-11-15 Finnfeeds Finland Ltd Glysiinibetaiinin käyttö verenpainetta alentavan tuotteen valmistukseen
GB0108930D0 (en) * 2001-04-10 2001-05-30 Boots Co Plc Therapeutic agents
US20040072750A1 (en) * 2001-05-03 2004-04-15 David Phillips Compounds and methods for the modulation of CD154
US6531171B2 (en) * 2001-07-03 2003-03-11 Nutricia Usa, Inc. Food products containing betaine
US20060160896A1 (en) * 2002-02-04 2006-07-20 Jallal Messadek Therapeutic treatment
US20030187074A1 (en) * 2002-03-04 2003-10-02 Javed Hussain Oral compositions for treatment of diabetes
JP4828795B2 (ja) * 2002-03-11 2011-11-30 モメンタ ファーマシューティカルズ インコーポレイテッド 硫酸化多糖類の分析
US7985422B2 (en) * 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
US20040067986A1 (en) * 2002-10-04 2004-04-08 Nathan Sassover Neuro-degenerative inhibitor, neuro-endocrine modulator, and neuro-cerebral metabolism enhancer
ES2278314T3 (es) * 2003-04-17 2007-08-01 Jallal Messadek Formulaciones orales para la liberacion controlada de la betaina.
US7097968B2 (en) * 2003-07-10 2006-08-29 General Atomics Methods and compositions for assaying homocysteine
US20060128657A1 (en) * 2003-08-04 2006-06-15 Jallal Messadek Selected betaines and their uses
US7115947B2 (en) * 2004-03-18 2006-10-03 International Business Machines Corporation Multiple dielectric finfet structure and method

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6235311B1 (en) * 1998-03-18 2001-05-22 Bristol-Myers Squibb Company Pharmaceutical composition containing a combination of a statin and aspirin and method
DE19910682A1 (de) * 1999-03-10 2000-09-21 Jutta Dierkes Kombination von Fibraten mit einem oder mehreren Wirkstoffen, die den Homocysteinspiegel zu senken vermögen
WO2002062322A2 (fr) * 2001-02-05 2002-08-15 Jallal Messadek Glycine-betaine et utilisation correspondante
WO2004049095A2 (fr) * 2002-11-25 2004-06-10 Jallal Messadek Compositions de betaine
WO2005011642A1 (fr) * 2003-08-05 2005-02-10 Galephar M/F Composition pharmaceutique a unite simple comprenant un melange de fibranne et un agent reducteur d'homocysteine

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MCCARTY M F: "Co-administration of equimolar doses of betaine may alleviate the hepatotoxic risk associated with niacin therapy", MEDICAL HYPOTHESES, vol. 55, no. 3, September 2000 (2000-09-01), pages 189 - 194, XP009059259, ISSN: 0306-9877 *

Also Published As

Publication number Publication date
ES2361284T3 (es) 2011-06-15
EP1773450B1 (fr) 2011-02-16
US20070134324A1 (en) 2007-06-14
PT1773450E (pt) 2011-05-18
ATE498427T1 (de) 2011-03-15
DE602005026394D1 (de) 2011-03-31
BE1016128A6 (fr) 2006-03-07
WO2006007671A2 (fr) 2006-01-26
EP1773450A2 (fr) 2007-04-18
DK1773450T3 (da) 2011-06-14
PL1773450T3 (pl) 2011-07-29

Similar Documents

Publication Publication Date Title
WO2006130628A3 (fr) Formulations pharmaceutiques et methodes de traitement utilisant ces formulations
WO2005032474A3 (fr) Compositions pharmaceutiques pour prevenir une dose excessive ou un abus
WO2008008364A3 (fr) Compositions liquides de phényléphrine à stabilité améliorée
WO2006041641A3 (fr) Agents therapeutiques a toxicite reduite
WO2006091529A3 (fr) Preparation pharmaceutique solide
WO2007126832A3 (fr) Compositions pharmaceutiques pour la prévention de la surdose ou de l'abus
WO2008057579A3 (fr) Formes dosifiées et co-administration d'un agoniste opioïde et d'un antagoniste opioïde
WO2006007671A3 (fr) Combinaisons therapeutiques
WO2007002597A3 (fr) Formulations a liberation modifiee d'un sel de bupropion
WO2003045306A3 (fr) Composes phenoxy amine et compositions pour administrer des principes actifs
WO2008042480A3 (fr) Inhibiteurs époxyde de cystéine protéases
WO2006005581A3 (fr) Composition contenant un agent pharmacologiquement actif couple a un composant specifique de cellules cibles, et saponine
WO2007066150A3 (fr) Administration de principes actifs par voie transdermique pour l'obtention d'un effet systemique
EP2279732A3 (fr) Composés et compositions pour la distribution d'agents actifs
WO2005110428A3 (fr) Inhibiteurs de protéase rétrovirale repoussant leur résistance
WO2006089114A3 (fr) Procedes et compositions pour le traitement d'un sujet souffrant d'un etat a mediation assuree par la toxine de l'anthrax
WO2007133944A3 (fr) Administration topique d'acyclovir
WO2009023355A3 (fr) Compositions et procédés pour réduire la toxicité de certaines toxines
WO2005117895A3 (fr) Compositions contenant de la meloxicame
IL181872A0 (en) Stable emulsion compositions for intravenous administration having preservative efficacy
EP2332526A3 (fr) combinaison d'un inhibiteur de rénine avec un agent anti-dyslipidémique ou un agent anti-obèse
EP1745793A4 (fr) Absorbant pour administration orale, agent thérapeutique ou préventif pour une maladie rénale et agent thérapeutique ou préventif pour une maladie hépatique
WO2002100338A3 (fr) Compose et composition permettant d'administrer des principes actifs
WO2007056142A3 (fr) Procedes de prevention du syndrome serotoninergique et compositions utilisees a cette fin
WO2005117940A3 (fr) Modulation de la mort cellulaire au moyen d'antagonistes de l'activation des fasl et fas

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 11625448

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2005763958

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2005763958

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 11625448

Country of ref document: US